BioSpace News Archive

Ambrx Biopharma Inc., or Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, announced that Feng Tian, Ph.D., President and Chief Executive Officer of Ambrx, will present at the 30th Annual Virtual Credit Suisse Healthcare Conference on Monday, November 8th, 2021, at 4:20 PM ET.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act date to February 28, 2022 for the ciltacabtagene autoleucel Biologics License Application.

Profound Medical Corp., a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced that management will participate in two investor conferences in November.

Bruker Corporation announced financial results for its third quarter and for the nine months ended September 30, 2021.

Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, will announce financial results for the third quarter of 2021 and recent corporate updates on Monday, November 8.

Inhibrx, Inc., a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced that the Company will be presenting at the Connective Tissue Oncology Society, or CTOS, 2021 Virtual Annual Meeting taking place November 10-13, 2021.

Telix Pharmaceuticals Limited announces that the Australian Therapeutic Goods Administration has approved Illuccix®, the Company’s lead prostate cancer imaging product.

ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that on October 29, 2021 the compensation committee of the Company’s Board of Directors granted a non-qualified stock option award to purchase 8,400 shares of its common stock to a new employee under the ImmunoGen, Inc. Inducement Equity Incentive Plan.

Antengene Corporation Limited announced that China’s National Medical Products Administration has approved an open-label Phase Ib dose-escalation study designed to assess the safety of ATG-008 in combination with ATG-010 in patients with relapsed/refractory diffuse large B-cell lymphoma.

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced that it has granted an inducement award to one new employee, Mohab Hassanin, who joined the Company as Clinical Trial Manager.